Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer

Published: Thursday, February 13, 2014
Last Updated: Thursday, February 13, 2014
Bookmark and Share
Second antibody from Ganymed’s ideal monoclonal antibody platform in the clinic.

Ganymed Pharmaceuticals AG has announced that the first patients are being enrolled and are starting treatment in a Phase I/II OVAR clinical trial to assess the safety, tolerability, and efficacy of IMAB027 as single agent for the treatment of advanced ovarian cancer.

IMAB027 is a highly specific monoclonal antibody targeting the tight junction protein Claudin-6 (CLDN6). The trial is being conducted in Germany, Belgium, Russia, and Ukraine.

“IMAB027 is the second antibody from Ganymed to enter clinical development that is based on our Ideal Monoclonal Antibody platform,” said Dr. Özlem Türeci, Chief Executive Officer and Chief Medical Officer of Ganymed.

Dr. Türeci continued, “Women with recurrent ovarian cancer have few therapeutic options. We believe that the unmatched cancer-cell selectivity of IMAB027 holds great promises of improving treatment options for these patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ganymed's IMAB362 Extends Survival in Gastric Cancer
IMAB362 nearly doubles survival in patients with the highest levels of Claudin18.2 to develop high target immunotherapy against cancer.
Tuesday, June 07, 2016
Ganymed Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Conference will take place from January 13 to January 16, 2014 in San Francisco.
Thursday, December 26, 2013
Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round
Company to accelerate clinical development of antibodies IMAB362 and IMAB027 for the treatment of cancer.
Monday, November 18, 2013
Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA
IMAB362 receives orphan drug designation for the treatment of pancreatic cancer.
Monday, October 21, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!